Clinical Trials in Salt Lake City

Showing 13621-13640 of 16,694 trials

Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation

NCT01546883

This study includes treating patients with atrial fibrillation (AF) with Dabigatran, an anti-coagulant for a period of one year to see if there are any significant changes in the degree of left atrial structural remodeling in these patients. The investigators hypothesize that there will be a significant decrease in the degree of left atrial structural remodeling (fibrosis) in AF patients treated with dabigatran.

Atrial Fibrillation

University of Utah14 participantsStarted Feb 2012

Salt Lake City, Utah, United States

COMPLETEDPhase 26.5 miles

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

NCT01369095

The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued Duloxetine/Escitalopram in the treatment of patients with treatment resistant depression (TRD).

Depression

Bristol-Myers Squibb976 participantsStarted Jul 2011

Birmingham, Alabama, United States • Little Rock, Arkansas, United States • Chino, California, United States +90 more locations

Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

Find Trials by Condition in Salt Lake City

Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients

PoC in Rheumatoid Arthritis With Methotrexate

Safety Study of BMS-770767 in Subjects With Type 2 Diabetes

A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease

Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

Pioglitazone in Early Parkinson's Disease

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

Brain Metastases In ErbB2-Positive Breast Cancer

Phase II, 2nd Line Melanoma - RAND Monotherapy

Ph IIA Study (SOC +/- NS5B)

Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer

Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types